Does anyone have any info on this contract? They are hiring in my area and I have an interview next week but haven't heard anything about pay, contract term, etc.
Take this job ONLY if you have too. Right now there is no product and just lost Medicaid coverage. The managers are great but the Lead is a nightmare! Micromanagment at its worst.
I have an interview with them as well. Not sure about pay etc.. yet. I found it strange they are going in as Quintiles and not Innovex which is who I knew them as. Seems like they are looking for experienced reps that are non-pharma. I was told contract has been around for 3 yrs already which sounds like to me could end tomorrow for all we know. I assume it is salary of $50-$60 plus around $10-$15k bonus at plan.
Wocking hard is the name of the game here. No slack offs need apply. Was hired a year ago and never see my wife and kids. Spend 24/7 wocking hard on this contract. Please forgive my mispronounciation. Would you like a side of flied lice with that! Now back to wanking my wock. Won Hung Lo
don't even interview. you will never make bonus, you can not sell what they do not have and they do not have product. incompetent, unethical, dishonest sums up this company (both Wockhardt and Innovex). It's not just the lead that micro-manages either.
For the reps that have worked or are working for the Wockhardt contract, what is the salary, is there car allowance etc?
Wockhardt say that my wocker wasn't hardt enough and needed some additional wok. Went to lab for wock-up and all they said was . . . . . . woman who fly upside down have cwack up! What's wock with them??
It's a pretty good deal if you have Medicaid coverage. It's possible to work smart and have great quality of life. Don't expect to ever get promoted or Ever make close to six figures.
Same Wockhardt? Wockhardt Managing Director Murtaza Khorakiwala Indian generic manufacturer Wockhardt has begun to feel the sting of an FDA ban on drugs made at two of its plants, with fourth quarter profits falling 78%. And worse may still be to come, with the FDA issuing a Form 483 to the facility in Illinois that is the engineroom of Wockhardt's U.S. business. Livemint reports Wockhardt's fourth quarter U.S. sales are estimated to have fallen more than 50% year-on-year, with the FDA import alert against two Indian facilities accounting for the decline. As the import alerts mounted up last year, the one bright spot for Wockhardt was the continued quality compliance of the Illinois-based unit that generates more than half of U.S. sales. Now this too is under threat. The Form 483 could be resolved without significantly affecting Wockhardt's business, but fears of another import alert loom. Wockhardt has taken steps to stop the situation from escalating by responding to FDA's observations, but the final outcome is unpredictable. "It's difficult to say what kind of position the FDA will take but according to us the inspection was not a very negative inspection," Wockhardt's Managing Director Murtaza Khorakiwala told analysts at a briefing attended by Reuters. Khorakiwala was equally unsure about how FDA will respond to its attempts to fix the two plants in India that have been under import alerts since last year. While Khorakiwala thinks the facilities have made "significant progress," the only available independent assessment comes from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA). Khorakiwala said the MHRA saw signs of improvement at the Chikalthana site, but is yet to lift the restrictions it imposed in 2013.
